Hikma Sees Field For Generic Of Advair Narrow As It Enrols Study
The challenges of developing a US generic of GlaxoSmithKline’s Advair Diskus fluticasone/salmeterol asthma blockbuster are thinning the field and improving the commercial prospects for those that succeed, Hikma believes.
You may also be interested in...
Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.
Hikma has submitted a response to the US FDA addressing all outstanding deficiencies in its application for a generic version of GlaxoSmithKline’s Advair Diskus.
Lannett has struck a deal giving it exclusive US distribution rights for 10 years to a generic version of Advair Diskus being developed by China’s Respirent.